

=>d-his

(FILE 'REGISTRY' ENTERED AT 10:51:19 ON 05 AUG 2004)
DEL HIS Y

L1 1 S 694483-56-2
E SUCROSE/CN
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:52:34 ON 05 AUG 2004

L3 1 S L1
L4 2911 S CSP OR CSP/AB OR (COMPETENCE STIMULAT? PEPTIDE?) /AB OR COMPET
L5 4570 S MUTANS OR MUTANS/AB
L6 8 S L4 AND L5
L7 15593 S DENTIFRIC? OR TOOTHPASTE? OR TOOTH DECAY OR CAVITIES OR MOUTHW
L8 2 S L7 AND L4
L9 1 S (COMPETENCE SIGNAL PEPTIDE?)
L10 1 S (COMPETENCE SIGNAL PEPTIDE?) /AB
L11 1 S L9 OR L10
L12 2 S L8 OR L11
L13 2 S L6 AND L7
L14 241943 S PEPTIDE# OR OLIGOPEPTIDE#
L15 21542 S L14 (L) THU/RL
L16 83 S L15 AND L7
L17 19 S L16 AND L5
L18 2 S L13 OR L12
L19 17 S L17 NOT L18

SYSTEM:OS - DIALOG OneSearch
File 652:US Patents Fulltext 1971-1975
(c) format only 2002 The Dialog Corp.
File 654:US Pat.Full. 1976-2004/Nov 04
(c) Format only 2004 The Dialog Corp.

Hold

Set Items Description
--- ---

Cost is in DialUnits

?ds

Set Items Description
S1 1411 HISTIDINE? (3N) KINASE?
S2 215 S1 (25N) (INHIBIT? OR ANTAGON? OR MODULAT? OR REGULAT? OR -
INACTIV? OR BLOCK? OR INACTIVA? OR NEUTRALI?)
S3 215 S2 AND (PEPTIDE? OR POLYPEPTIDE? OR PROTEIN?)
S4 196 S2 (50N) (PEPTIDE? OR POLYPEPTIDE? OR PROTEIN?)
S5 81 S4 AND SUCROS?
S6 4 S4 (100N) SUCROS?
S7 0 S1 (25N) SUCROS?
S8 1094 S1 AND SUCROS? NOT S6
S9 6 S1 (100N) SUCROS?
S10 2 S9 NOT S6
S11 138 S3 AND (MOUTH? OR TEETH? OR TOOTHPASTE? OR ORAL?)
S12 97 S3 (100N) (MOUTH? OR TEETH? OR TOOTHPASTE? OR ORAL?)
S13 39 S12 AND SUCROS?
?s s13 and histidin?
39 S13
41596 HISTIDIN?
S14 39 S13 AND HISTIDIN?

?t s14/3,kwic/all

14/3,KWIC/1 (Item 1 from file: 654)

DIALOG(R) File 654:US Pat.Full.

(c) Format only 2004 The Dialog Corp. All rts. reserv.

0005851541 **IMAGE Available

Compositions and methods for treatment of neoplastic disease

Inventor: Terman, David, INV

Correspondence Address: VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O.

BOX 34385, WASHINGTON, DC, 20043-9998, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20040214783	A1	20041028	US 2003428817	20030505
Provisional				US 60-378988	20020508
Provisional				US 60-389366	20020615
Provisional				US 60-406697	20020828
Provisional				US 60-406750	20020829
Provisional				US 60-415310	20021001
Provisional				US 60-415400	20021002
Provisional				US 60-438686	20030109

Fulltext Word Count: 196133

Description of the Invention:

...is engineered such that the resulting SAg is devoid of amino acid residues, e.g., **histidine**, known to produce toxicity. Likewise, SAg-encoding nucleic acid is engineered to contain or lack...The eta gene is by the agr gene regulator which is a member of the **histidine**-protein kinase response regulator superfamily. (Patrick S et al., Immunological and Molecular Aspects of Bacterial...with different types of host cells. There is also evidence that immunopotentiating activity of a **glycopeptide** produced by mycobacteria is dependent on the saccharide residues of the molecule...Proc. Natl. Acad. Sci. USA. 92:1619-1623 (1995)). These proteins are members of the **histidine** protein kinase